A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf.
The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers
2013
Canadian Urological Association Journal
Preserved Fulltext
Prostate cancers in patients with a mutation in BRCA2 have earlierdisease onset and an aggressive course, often necessitatingthe use of systemic therapy. However, these tumours are DNArepair-defective and could respond favourably to Parp inhibitors orDNA-damaging agents, depending on the therapeutic ratio (ratio oftumour response to normal tissue toxicity). We describe 3 patientstreated with precision radiotherapy or cisplatin who respondedfavourably to both agents, yet did not suffer undue
doi:10.5489/cuaj.619
fatcat:mci5aydpjnatddiwiawibnkb7u